TY - JOUR
T1 - Candidemia in a tertiary care hospital
T2 - Epidemiology, risk factors, and predictors of mortality
AU - Fraser, Victoria J.
AU - Jones, Marilyn
AU - Dunkel, John
AU - Storfer, Stephen
AU - Medoff, Gerald
AU - Claiborne Dunagan, W.
N1 - Funding Information:
Received 28 January 1992; revised 25 March 1992. Presented in part at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. October 1991. Grant support: This work was supported in part by the U.S. Public Health Service (grant no. AI-07ln). Reprints or correspondence: Dr. Victoria Fraser, Box 8051, Infectious Disease. 660 South Euclid, St. Louis. Missouri 63110.
PY - 1992/9
Y1 - 1992/9
N2 - Demographic information, risk factors, therapy, and outcome for all patients who had candidemia at Barnes Hospital, St. Louis, between 1 September 1988 and 1 September 1989 were retrospectively reviewed. One hundred six candidemic patients were identified, representing 0.5% of all medical and surgical discharges and 0.33% of total patient discharges. These percentages represent a 20-fold increase in the incidence of candidemia at our hospital in comparison with that during 1976-1979. Candida albicans was the most frequently isolated species (63%), followed by Candida tropicalis (17%), Candida glabrata (13%), Candida parapsilosis (6.5%), and Candida krusei (0.9%). Overall mortality was 57%, and 14 (23%) of 60 deaths occurred within 48 hours of the detection of candidemia. Mortality was associated with higher APACHE II scores (25 for nonsurvivors vs. 16 for survivors; P = 0001), the presence of a rapidly fatal underlying illness (P = 0009), and sustained positivity of blood cultures (P = 02). In cases of sustained candidemia, the isolation of non-albicans Candida species also correlated with increased mortality (8 of 8 vs. 10 of 21; P = 005). Thirty candidemic patients (28%) did not receive any antifungal therapy, and 19 (63%) of these untreated patients died. Eleven untreated patients (37%) survived without sequelae. There has been a marked increase in the incidence of candidemia in our institution that is associated with a high overall mortality. Candidemia lasting <24 hours was associated with a lower mortality than was that of longer duration. Severity of illness and duration of candidemia should be used as stratifying factors in prospective studies to determine optimum therapy.
AB - Demographic information, risk factors, therapy, and outcome for all patients who had candidemia at Barnes Hospital, St. Louis, between 1 September 1988 and 1 September 1989 were retrospectively reviewed. One hundred six candidemic patients were identified, representing 0.5% of all medical and surgical discharges and 0.33% of total patient discharges. These percentages represent a 20-fold increase in the incidence of candidemia at our hospital in comparison with that during 1976-1979. Candida albicans was the most frequently isolated species (63%), followed by Candida tropicalis (17%), Candida glabrata (13%), Candida parapsilosis (6.5%), and Candida krusei (0.9%). Overall mortality was 57%, and 14 (23%) of 60 deaths occurred within 48 hours of the detection of candidemia. Mortality was associated with higher APACHE II scores (25 for nonsurvivors vs. 16 for survivors; P = 0001), the presence of a rapidly fatal underlying illness (P = 0009), and sustained positivity of blood cultures (P = 02). In cases of sustained candidemia, the isolation of non-albicans Candida species also correlated with increased mortality (8 of 8 vs. 10 of 21; P = 005). Thirty candidemic patients (28%) did not receive any antifungal therapy, and 19 (63%) of these untreated patients died. Eleven untreated patients (37%) survived without sequelae. There has been a marked increase in the incidence of candidemia in our institution that is associated with a high overall mortality. Candidemia lasting <24 hours was associated with a lower mortality than was that of longer duration. Severity of illness and duration of candidemia should be used as stratifying factors in prospective studies to determine optimum therapy.
UR - http://www.scopus.com/inward/record.url?scp=0026737730&partnerID=8YFLogxK
U2 - 10.1093/clind/15.3.414
DO - 10.1093/clind/15.3.414
M3 - Article
C2 - 1520786
AN - SCOPUS:0026737730
SN - 1058-4838
VL - 15
SP - 414
EP - 421
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 3
ER -